GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyne Therapeutics Inc (NAS:DYN) » Definitions » 3-Year ROIIC %

Dyne Therapeutics (Dyne Therapeutics) 3-Year ROIIC % : -507.23% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Dyne Therapeutics 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Dyne Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was -507.23%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Dyne Therapeutics's 3-Year ROIIC % or its related term are showing as below:

DYN's 3-Year ROIIC % is ranked worse than
87.87% of 1418 companies
in the Biotechnology industry
Industry Median: -15.155 vs DYN: -507.23

Dyne Therapeutics 3-Year ROIIC % Historical Data

The historical data trend for Dyne Therapeutics's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyne Therapeutics 3-Year ROIIC % Chart

Dyne Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year ROIIC %
Get a 7-Day Free Trial - - -308.65 -359.88 -507.23

Dyne Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -359.88 - - - -507.23

Competitive Comparison of Dyne Therapeutics's 3-Year ROIIC %

For the Biotechnology subindustry, Dyne Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyne Therapeutics's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyne Therapeutics's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Dyne Therapeutics's 3-Year ROIIC % falls into.



Dyne Therapeutics 3-Year ROIIC % Calculation

Dyne Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -242.162 (Dec. 2023) - -58.647 (Dec. 2020) )/( 40.427 (Dec. 2023) - 4.247 (Dec. 2020) )
=-183.515/36.18
=-507.23%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Dyne Therapeutics  (NAS:DYN) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Dyne Therapeutics 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Dyne Therapeutics's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyne Therapeutics (Dyne Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1560 Trapelo Road, Waltham, MA, USA, 02451
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
Executives
Dirk Kersten director, 10 percent owner C/O FORBION CAPITAL FUND IV COOPERATIEF, GOOMIER 2-35, NAARDEN P7 14111 DC
Joshua T Brumm director, officer: See Remarks ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Jonathan Mcneill officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Oxana Beskrovnaya officer: See Remarks C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Richard William Scalzo officer: See Remarks 25 ALBERTA LANE, HOLLISTON MA 01746
Wildon Farwell officer: Chief Medical Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET MA 02451
Susanna Gatti High officer: Chief Operating Officer 75 LORIMER ROAD, BELMONT MA 02141
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Jason P Rhodes director, 10 percent owner C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Carlo Incerti director FORBION CAPITAL FUND IV COOPERAITEF U.A., GOOMIER 2-35, NAARDEN P7 1411DC
Romesh Subramanian 10 percent owner, officer: Chief Scientific Officer C/O DYNE THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Cureduchenne Ventures, Llc 10 percent owner 1400 QUAIL STREET, SUITE 110, NEWPORT BEACH CA 92660